BeOne Medicines (ONC)
381.84
-4.62 (1.20%)
Upcoming Events
Latest Headlines
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
October 22, 2026 6:01 AM - BizWire
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
October 19, 2026 6:00 AM - BizWire
BeOne Medicines (ONC) PT Raised to $425 at Morgan Stanley
October 16, 2026 8:42 AM - StreetInsider
Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings
October 16, 2026 6:23 AM - StreetInsider
Form 4 BeOne Medicines Ltd. For: Oct 13 Filed by: Wang Xiaodong
October 15, 2026 5:09 PM - SEC Filing
BeOne Medicines (ONC) PT Raised to $459 at RBC Capital
October 8, 2026 8:27 AM - StreetInsider
BeOne Medicines (ONC) PT Raised to $420 at Truist Securities
October 7, 2026 7:13 AM - StreetInsider
Form 4 BeOne Medicines Ltd. For: Sep 30 Filed by: Lee Chan Henry
October 2, 2026 4:53 PM - SEC Filing
BeOne Medicines (ONC) PT Raised to $445 at JPMorgan
October 1, 2026 9:06 AM - StreetInsider
Form 4 BeOne Medicines Ltd. For: Sep 28 Filed by: Wang Xiaodong
September 30, 2026 5:11 PM - SEC Filing
Form 4 BeOne Medicines Ltd. For: Sep 14 Filed by: BAKER JULIAN
September 18, 2026 6:47 PM - SEC Filing
BeOne Medicines (ONC) Reiterated at Market Outperform by Citizens on Serial Innovation
September 15, 2026 5:31 AM - StreetInsider
Form 4 BeOne Medicines Ltd. For: Sep 08 Filed by: Wang Xiaodong
September 10, 2026 4:50 PM - SEC Filing
BeOne Medicines (ONC) PT Raised to $415 at Barclays
September 10, 2026 5:06 AM - StreetInsider
Form 4 BeOne Medicines Ltd. For: Aug 25 Filed by: Wu Xiaobin
August 27, 2026 5:13 PM - SEC Filing
FDA approves BeOne's Tevimbra combo for HER2+ stomach cancer
August 25, 2026 10:40 AM - StreetInsider
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
August 25, 2026 10:40 AM - BizWire
BeOne Medicines renews CLL drug access deal for low-income nations
August 18, 2026 6:00 AM - StreetInsider
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
August 18, 2026 6:00 AM - BizWire
Form 4 BeOne Medicines Ltd. For: Aug 11 Filed by: Lee Chan Henry
August 13, 2026 8:55 PM - SEC Filing
Form 4 BeOne Medicines Ltd. For: Aug 10 Filed by: OYLER JOHN
August 12, 2026 5:53 PM - SEC Filing
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
August 10, 2026 6:00 AM - BizWire
BeOne Medicines (ONC) PT Raised to $405 at Morgan Stanley
August 6, 2026 8:50 AM - StreetInsider
BeOne Medicines (ONC) PT Raised to $454 at TD Cowen
August 6, 2026 8:07 AM - StreetInsider
BeOne Medicines (ONC) PT Raised to $418 at Truist Securities
August 6, 2026 7:21 AM - StreetInsider
BeOne Medicines (ONC) PT Raised to $430 at Guggenheim
August 6, 2026 6:44 AM - StreetInsider
BeOne Medicines (ONC) PT Lowered to $450 at RBC Capital
August 6, 2026 6:43 AM - StreetInsider
BeOne Medicines (ONC) PT Raised to $405 at Citizens
August 6, 2026 6:31 AM - StreetInsider
BeOne Medicines (ONC) PT Raised to $407 at Barclays
August 6, 2026 4:18 AM - StreetInsider
Form 4 BeOne Medicines Ltd. For: Aug 03 Filed by: Rosenberg Aaron
August 5, 2026 5:16 PM - SEC Filing
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
August 5, 2026 6:00 AM - BizWire
Form 4 BeOne Medicines Ltd. For: Jul 30 Filed by: Lee Chan Henry
August 3, 2026 5:18 PM - SEC Filing
Form 4 BeOne Medicines Ltd. For: Jul 22 Filed by: Lee Chan Henry
July 24, 2026 4:51 PM - SEC Filing
Full Article List
